Vyant Bio, Inc. (VYNT)
| Market Cap | 120.58M |
| Revenue (ttm) | 5.75M |
| Net Income (ttm) | -8.00M |
| Shares Out | 2.53M |
| EPS (ttm) | -3.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 9 |
| Last Price | $4.02 |
| Previous Close | $4.18 |
| Change ($) | -0.16 |
| Change (%) | -3.83% |
| Day's Open | 4.15 |
| Day's Range | 3.94 - 4.32 |
| Day's Volume | 619,120 |
| 52-Week Range | 2.11 - 17.50 |
CHERRY HILL, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-bas...
CHERRY HILL, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and technology-base...
Cancer Genetics, Inc. Renamed to Vyant Bio, Inc.
Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline o...
RUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief ...
RUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief ...
RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...
RUTHERFORD, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...
Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above estimates. ...
Cancer Genetics said its board has approved the StemoniX merger, setting the stage for a March shareholder vote. In the wake of the move, investors drove up the CGIX stock price in Wednesday's premarket...
RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...
RUTHERFORD, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...
RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief E...
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cancer Genetics, Inc. ("CGIX" or the "C...
RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced toda...
Rutherford, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or “the Company”), a leader in drug discovery and preclinical oncology and immuno-oncology ser...
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced ...
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in in drug discovery and preclinical oncology and immuno-oncology services, announc...
MUMBAI, India and LONDON, Sept. 28, 2020 /PRNewswire/ -- A landmark study published in the American Association of Cancer Research's (AACR) prestigious journal 'Cancer Prevention Research' has shown tha...
NEW YORK, Sept. 26, 2020 /PRNewswire/ -- Cancer Genetics, Inc. (NASDAQ: CGIX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger wi...
RUTHERFORD, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today annou...
RUTHERFORD, N.J., and MAPLE GROVE, MN, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, and St...
NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York Cit...
NEW YORK, Aug. 26, 2020 /PRNewswire/ -- Cancer Genetics, Inc.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Wilmington, Delaware--(Newsfile Corp. - August 25, 2020) - Rigrodsky & Long, P.A.
NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Cancer Genetics, Inc.
New York, New York--(Newsfile Corp. - August 24, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cancer Genetics, Inc.
Cancer Genetics (NASDAQ: CGIX) shares are trading higher on Monday after the company announced the entry into a definitive merger agreement with StemoniX.
Cancer Genetics Inc. (NASDAQ: CGIX) shares more than doubled on Monday after the company announced a merger with StemoniX.
Cancer Genetics' news of a merger with major drug developer StemoniX has CGIX stock skyrocketing higher on Monday morning. The post Cancer Genetics News: Why CGIX Stock Is Rocketing Today appeared first...
Combined Company Positioned to Offer Best-in-Class and Innovative Drug Discovery Solutions
RUTHERFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced ye...
Investors have had a love affair with the market around underwritten initial public offerings for many years, but the other side of the underwriting world revolves around secondary offerings and capital...
Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates
RUTHERFORD, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announ...
RUTHERFORD, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or the “Company”), a leader in drug discovery and preclinical oncology and immuno-oncology s...
RUTHERFORD, N.J., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, f...
Note Payment Received from Interpace Diagnostics Group, Inc.
RUTHERFORD, N.J, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will ...
Cancer Genetics Reports Second Quarter 2019 Financial Results and Provides Strategic Business Update
RUTHERFORD, N.J., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, f...
Cancer Genetics (NASDAQ: CGIX) shares are trading sharply higher after Interpace Diagnostics (NASDAQ: IDXG) said it purchased the Biopharma Services unit of the Cancer Genetics.
About VYNT
There is no company description available.
| Industry Medical Laboratories | IPO Date Apr 5, 2013 |
| CEO John Roberts | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol VYNT |
Financial Performance
In 2020, Vyant Bio's revenue was $5.75 million, a decrease of -21.27% compared to the previous year's $7.31 million. Losses were -$8.00 million, 19.3% more than in 2019.